Merit Medical Systems(NASDAQ) MMSI

Merit makes single-use tools that doctors use to treat patients during specialized medical procedures. These products help medical teams manage blood flow and reach target organs in cardiology, radiology, and oncology. The company sells its equipment to hospitals and clinics through a global network of sales teams and distributors.

What Does Merit Make?

• Foundational products: Tools used to access blood vessels and support surgical procedures; these generated $255.5 million of net sales in Q1 2026.
• Therapeutic products: Specialized devices used to treat diseases in the heart, kidneys, and lungs; these accounted for $126.4 million of net sales in Q1 2026.
• Endoscopy products: Devices such as stents and balloons used to examine and open strictures in the stomach or lungs.
• Custom procedural solutions: Combined kits containing syringes and specialized trays for use in critical care and operating rooms.

Building Through New Deals

• Acquired Biolife in May 2025 to add unique blood-clotting devices sold under the StatSeal and WoundSeal brands.
• Purchased the C2 CryoBalloon technology from Pentax in November 2025 to expand offerings in the endoscopy market.
• Completed the sale of the DualCap product line to Health Line in February 2026 for $28 million.
• Merged with View Point Medical in April 2026 to acquire imaging markers used in medical detection systems.
• Bought assets from Cook Medical Holdings LLC in November 2024 and EndoGastric Solutions, Inc. in July 2024.

Getting Tools to Doctors

Merit reaches hospitals through a mix of direct sales teams and partners across domestic and international markets. The company operates as a single segment to simplify how it manages global resources and tracks financial performance.

Success by the Numbers

• Net sales rose to $381.9 million in Q1 2026, a 7.5% increase compared to Q1 2025.
• Net income grew to $41 million in Q1 2026, up 36% from the previous year.
• Free cash flow reached $24.7 million in Q1 2026, a 29.5% increase year-over-year.
• International sales hit $155.4 million in Q1 2026, up 9.6% from the prior-year period.
• Cash and equivalents totaled $488.1 million as of March 31, 2026.

Bottom Line

Merit has transitioned to a unified business model focused on core medical tools. Its recent acquisitions and divestitures show a clear shift toward high-demand therapeutic and endoscopy technologies.